Synchron key facts
as of Oct 2026- Developer of an implantable stent-rode designed to create a brain-computer interface.
- Synchron is valued at approximately $385.0M as of Oct 2026, set at its later-stage round, Dec 2022; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $339.9M across 1 recorded rounds; the latest was Early Stage VC ($49.9M) in Nov 2022.
- Notable investors include Alumni Ventures, Khosla Ventures, United States Department of War, National Institutes of Health, In-Q-Tel — 47 tracked in total.
- PrivateMarketView tracks 11 recorded secondary trades in Synchron shares.
- 4 investment vehicles were formed to buy Synchron shares in the last 12 months, reporting $6.8M sold to 158 investors, per SEC Form D filings.
- Synchron has filed 1 Form D with the SEC, most recently Dec 2022 ($49.9M sold to 22 investors).
- Status: Privately Held (backing).
Valued at $385.0M at its later-stage round, Dec 2022. Nothing has traded since.
Membership and data by Private Market View
- ·The complete investor list: 47 names
- ·Watch Synchron: the Monday email on marks, rounds and moves
Synchron secondary trades
11 on record · Oct 2025 – Jun 202611 trades between Oct 2025 and Jun 2026. Exact dates, prices and structures are available to Pro members.
Membership and data by Private Market View
Synchron funding rounds
1 roundsVehicles formed to buy Synchron shares
secondary demand · SEC Form D filingsIn the last 12 months, 4 investment vehicles were formed to buy Synchron shares, reporting $6.8M sold to 158 investors across 4 sponsors. Most recent filing May 2026.
Membership and data by Private Market View
Who backs Synchron
47+Synchron valuation
Synchron was valued at $385 million at its later-stage round in Dec 2022. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Synchron raised?
Synchron has raised $340 million in total; 1 of its rounds is on record. The largest on record was a $49.9 million early-stage round in Nov 2022.
Synchron has filed 1 Form D with the SEC, most recently in Dec 2022 ($49.9 million sold to 22 investors).
Synchron secondary market activity
11 secondary trades in Synchron shares are on record, between Oct 2025 and Jun 2026. The busiest recent months were Jun 2026 (4 prints) and Dec 2025 (3 prints). Exact dates, prices and structures are available to Pro members.
Institutional holders and vehicles
In the last 12 months, 4 investment vehicles were formed to buy Synchron shares, reporting $6.8 million sold to 158 investors across 4 sponsors, per SEC Form D filings (most recent May 2026).
Synchron investors
47 investors are on record for Synchron, including Alumni Ventures, Khosla Ventures, United States Department of War and National Institutes of Health. By type, the record holds 12 venture capital firms and 1 family office. The early-stage round in Nov 2022 drew 22 investors.
About Synchron
Developer of an implantable stent-rode designed to create a brain-computer interface. The company offers a minimally invasive implantable device embedded with electrode arrays that interpret signals from the brain to modulate neural activity in specific regions, enabling patients with motor impairments to regain some level of control over digital devices, prosthetics, or other assistive technologies using their thoughts.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2016
- Employees
- 127
- Website
- synchron.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.